@article {Knapskog:2016:0893-0341:8,
title = "Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway",
journal = "Alzheimer Disease & Associated Disorders",
parent_itemid = "infobike://wk/wad",
publishercode ="wk",
year = "2016",
volume = "30",
number = "1",
publication date ="2016-01-01T00:00:00",
pages = "8-14",
itemtype = "ARTICLE",
issn = "0893-0341",
eissn = "1546-4156",
url = "https://www.ingentaconnect.com/content/wk/wad/2016/00000030/00000001/art00002",
doi = "doi:10.1097/WAD.0000000000000126",
keyword = "Alzheimer disease, mild cognitive impairment, memory clinic, cerebrospinal biomarkers",
author = "Knapskog, Anne-Brita and Engedal, Knut and Braekhus, Anne",
abstract = "
Background:
Although Alzheimer disease (AD) remains a clinical diagnosis, biomarkers are in use to support the diagnosis. Three cerebrospinal biomarkers, amyloid- (A), total tau (T-tau), and phospho tau (P-tau), reflect neuropathologic changes observed in AD patients.
Objective:
The
aim of this study was to explore the performance of the cerebrospinal fluid biomarkers used in a memory clinic setting.
Methods:
We included 205 patients who had been through a standardized examination including lumbar puncture. Diagnoses were made blind to the results of
the spinal fluid analyses.
Results:
By combining low A and high T-tau or P-tau values, the sensitivity was 31.9% and the specificity was 92.5% when comparing patients with AD with other patients. In receiver operating characteristic analyses, the AUC for the A
was 0.78 (SE=0.04; 95% CI, 0.7-0.85), for T-tau 0.80 (SE=0.03; 95% CI, 0.73-0.86), and for P-tau 0.76 (SE=0.04; 95% CI, 0.69-0.83). A significant difference was found between the sexes, with higher values of A among younger men (under 65 y of age) with AD [799.8 (SD=317.2) vs. 558.9
(SD=123.5) for women, P-value=0.003].
Conclusions:
The present study found a lower performance of the biomarkers than reported previously.",
}